FDB (First Databank) vs Micromedex (2026)
The two drug knowledge incumbents. Few buyers choose between them the way this page implies, because many already own both: FDB sits inside the prescribing systems, Micromedex on the reference shelf. The comparison becomes real when a health system asks which drug content it wants an AI product grounded in. Micromedex is recognized as a drug compendium under United States federal law, which gives its content standing in coverage decisions, and it has a peer reviewed usability evaluation behind it. FDB's content is licensed into the systems of most American hospitals, practices and pharmacies. Both state business associate status and both publish AI principles. Neither names a security certification of its own or publishes a price.
- Its drug databases are embedded in the systems used by most American hospitals, practices and pharmacies, so most interaction and dose warnings clinicians see are built on this content.
- Content is licensed into customers' own systems, which places hosting, residency and processing questions with those customers rather than with the supplier.
- Its newer products are framed conservatively, with a prescription agent queuing orders for clinician review and the verification product named as an assistant rather than a decision maker.
- It is recognized as a drug compendium under United States federal law, so coverage and reimbursement decisions can reference it directly.
- A peer reviewed usability evaluation of the combined drug and disease product was published in 2023 by authors from Brigham and Women's Hospital and Harvard Medical School.
- Every result carries a citation that opens the underlying source in one click, over a corpus curated from primary literature and updated daily.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. FDB (First Databank) and Micromedex are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | FDB (First Databank) | Micromedex |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Clinical Reference & Evidence |
| Headquarters | South San Francisco, California, United States | Ann Arbor, Michigan |
| Website | fdbhealth.com | merative.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
FDB (First Databank)
-
Product / capability
FDB commercially deployed FDB Script Agent, an AI prescribing tool that converts ambient patient encounter dialogue directly into structured prescriptions.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
FDB, formerly First Databank, supplies the drug knowledge that sits underneath most medication decisions made in the United States. Its databases are integrated into the systems used by most hospitals, physician practices and pharmacies, which means that when a prescribing system warns about an interaction, a dose ceiling or a contraindication, the content behind that warning is frequently this company's rather than the software vendor's.
Source: AI Health Index, September 2026
Drug and toxicology reference from Merative, the company formed in June 2022 when Francisco Partners acquired the Watson Health assets from IBM. Headquartered in Ann Arbor, Michigan; Merative chief executive Gerry McCarthy, with Sonika Mathur as general manager for Micromedex. Content is curated by clinical experts from primary literature with in line referencing and daily updates, and is used in more than 80 countries by providers, poison control centers, government departments, universities, pharmaceutical organizations and health plans.
Source: AI Health Index, September 2026
Questions buyers ask
How do FDB (First Databank) and Micromedex handle patient data?
For FDB (First Databank), the licensed databases themselves are delivered inside customers' systems. The agentic products change the exposure: MedProof MCP serves knowledge in patient specific context, so patient details reach FDB on each tailored query, and Script Agent processes spoken clinical conversation.
With Micromedex, the clinician reference needs no patient record to work; the payer offering, which supports coverage determinations and claims adjudication, sits closer to member data, and the boundary is not described. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
What evidence is published for FDB (First Databank) and Micromedex?
In FDB (First Databank)'s case, the most notable absence is any comparison of whether agents grounded on FDB content give safer answers than agents that are not.
For Micromedex, the peer reviewed study measured usability rather than correctness, evaluated an earlier assistant two years before the current AI search, and was coauthored by the vendor; KLAS measures customer experience, and the compendium designation covers content rather than the model built over it. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Neither publishes a price. Merative publishes nothing on how Micromedex is sold, while FDB describes selling through the record and pharmacy system vendors that embed its content. Neither names a SOC 2, HITRUST or ISO 27001 certification of its own; Merative commits to annual independent penetration testing. FDB states its business associate role in its privacy notice, and Merative in its contract terms.
The exposure specific to FDB is concentration rather than discrimination: when one curated knowledge base sits underneath most medication decisions in a country, a gap propagates everywhere at once. FDB publishes the Hearst Health AI Principles and Merative its own, and neither publishes results for its AI features.